Cargando…

48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis

BACKGROUND: A network meta-analysis can provide estimates of relative efficacy for treatments not directly studied in head-to-head randomized controlled trials. We estimated the relative efficacy and safety of dolutegravir (DTG) versus third agents currently recommended by guidelines, including rito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Dipen A., Snedecor, Sonya J., Tang, Wing Yu, Sudharshan, Lavanya, Lim, Jessica W., Cuffe, Robert, Pulgar, Sonia, Gilchrist, Kim A., Camejo, Rodrigo Refoios, Stephens, Jennifer, Nichols, Garrett
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154896/ https://www.ncbi.nlm.nih.gov/pubmed/25188312 http://dx.doi.org/10.1371/journal.pone.0105653

Ejemplares similares

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada
por: Despiégel, Nicolas, et al.
Publicado: (2015)

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
por: Raffi, François, et al.
Publicado: (2015)

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2022)

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1
por: Evitt, Lee A., et al.
Publicado: (2023)

Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017)

Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis
por: Snedecor, Sonya J., et al.
Publicado: (2019)

Associations between signs and symptoms of dry eye disease: a systematic review
por: Bartlett, Jimmy D, et al.
Publicado: (2015)

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
por: Mulindwa, Frank, et al.
Publicado: (2023)

Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis
por: Nickel, Katharina, et al.
Publicado: (2021)

Correction to: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis
por: Nickel, Katharina, et al.
Publicado: (2021)

48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort
por: Cabello-Ubeda, Alfonso, et al.
Publicado: (2022)

Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection
por: Chounta, Vasiliki, et al.
Publicado: (2022)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

875. Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1 Infected Participants
por: Snedecor, Sonya J, et al.
Publicado: (2021)

Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks
por: Quercia, Romina, et al.
Publicado: (2015)

Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury
por: Snedecor, Sonya J, et al.
Publicado: (2013)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study
por: Stellbrink, Hans-Jürgen, et al.
Publicado: (2013)

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients
por: Zhang, Jianping, et al.
Publicado: (2015)

Weight gain in patients starting Dolutegravir-based ART according to baseline CD4 count after 48 weeks of follow up
por: Cardoso-Neto, Érico C., et al.
Publicado: (2023)

Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients
por: Radford, Matthew, et al.
Publicado: (2019)

Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups
por: Rawlings, M Keith, et al.
Publicado: (2022)

Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe
por: Kouamou, Vinie, et al.
Publicado: (2023)

Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks
por: Jörimann, Lisa, et al.
Publicado: (2023)

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
por: Mulindwa, Frank, et al.
Publicado: (2023)

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
por: Mulindwa, Frank, et al.
Publicado: (2023)

Factors Predicting the Efficacy of Adefovir Dipivoxil on Treatment-Naïve Chronic Hepatitis B Patients at 48 Weeks
por: Wang, Li-Chun, et al.
Publicado: (2011)

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
por: Mandikiyana Chirimuta, Linda A., et al.
Publicado: (2022)

Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV
por: Martínez-Sanz, Javier, et al.
Publicado: (2022)

Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial: Erratum
Publicado: (2016)

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
por: Molina, Jean-Michel, et al.
Publicado: (2014)

Bone Deleterious Effects of Different NRTIs in Treatment-naïve HIV Patients After 12 and 48 Weeks of Treatment
por: Atencio, Patricia, et al.
Publicado: (2021)

Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial
por: Walmsley, Sharon, et al.
Publicado: (2015)

1582. Dolutegravir/Rilpivirine STR Switch Study in Persons with HIV-1 and Chronic Kidney Disease: 48-week Assessment of Viral Suppression, Treatment Adherence and Quality of Life
por: Kwakwa, Helena, et al.
Publicado: (2023)

Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV
por: Saborido-Alconchel, Abraham, et al.
Publicado: (2023)

Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients
por: Valdez, H, et al.
Publicado: (2010)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naïve Patients with HBeAg Positive Chronic Hepatitis B
por: Kim, In Hee, et al.
Publicado: (2010)

Baracle(®) vs Baraclude(®) for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety
por: Kim, Do Young, et al.
Publicado: (2017)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gr138djhcie3v4bfgf8qu38rch